Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID DTD0019 Transporter Info
Gene Name SLC10A1
Transporter Name Sodium/taurocholate cotransporting polypeptide
Gene ID
6554
UniProt ID
Q14973
Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)

Approved Drug

  Cyclosporine

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cyclosporine inhibits the transportation of Rosuvastatin by SLC10A1 (IC50 = 0.37 microM) [1]

Affected Drug/Substrate

 Rosuvastatin Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-NTCP

  DT Modulation 2

 Cyclosporine inhibits the transportation of Sodium taurocholate by SLC10A1 (IC50 = 1 microM) [2]

Affected Drug/Substrate

 Sodium taurocholate Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-NTCP

  Bosentan

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Bosentan inhibits the transportation of Sodium taurocholate by SLC10A1 (Ki = 18 microM) [3]

Affected Drug/Substrate

 Sodium taurocholate Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-NTCP

  DT Modulation 2

 Bosentan inhibits the activity of SLC10A1 [3]

  Gemfibrozil

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Gemfibrozil inhibits the transportation of Rosuvastatin by SLC10A1 (IC50 = 23 microM) [1]

Affected Drug/Substrate

 Rosuvastatin Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-NTCP

  Chenodeoxycholic acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Chenodeoxycholic acid inhibits the transportation of Sodium taurocholate by SLC10A1 (IC50 = 3.6 microM) [2]

Affected Drug/Substrate

 Sodium taurocholate Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-NTCP

  Furosemide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Furosemide inhibits the transportation of Sodium taurocholate by SLC10A1 (IC50 = 15 microM) [2]

Affected Drug/Substrate

 Sodium taurocholate Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-NTCP

  Ketoconazole

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ketoconazole inhibits the transportation of Sodium taurocholate by SLC10A1 (IC50 = 264 microM) [2]

Affected Drug/Substrate

 Sodium taurocholate Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-NTCP

  Propranolol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Propranolol inhibits the transportation of Sodium taurocholate by SLC10A1 (IC50 = 5.5 microM) [2]

Affected Drug/Substrate

 Sodium taurocholate Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-NTCP

  Chlorpropamide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Chlorpropamide inhibits the transportation of Sodium taurocholate by SLC10A1 [2]

Affected Drug/Substrate

 Sodium taurocholate Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-NTCP

  Progesterone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Progesterone inhibits the transportation of Sodium taurocholate by SLC10A1 [2]

Affected Drug/Substrate

 Sodium taurocholate Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-NTCP

  Caspofungin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Caspofungin inhibits the transportation of Sodium taurocholate by SLC10A1 [6]

Affected Drug/Substrate

 Sodium taurocholate Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-NTCP

  Everolimus

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Everolimus inhibits the uptake of taurocholate by SLC10A1 [7]

Affected Drug/Substrate

 Taurocholate Modulation Type Inhibition

Cell System

 Human hepatoma HuH-7 cells-NTCP1

  Cholic Acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cholic Acid inhibits the expression of SLC10A1 [9]

Regulation Mechanism

 via modulation of Bile acid receptor (NR1H4) Transcription Factor Info

Cell System

 C57/BL6 mice

  Phenobarbital

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Phenobarbital inhibits the expression of SLC10A1 [10]

Regulation Mechanism

 via modulation of Nuclear receptor subfamily 1 group I member 3 (NR1I3) Transcription Factor Info

Cell System

 Human primary human hepatocytes

  Cocaine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cocaine inhibits the expression of SLC10A1 [11]

  Obeticholic acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Obeticholic acid inhibits the expression of SLC10A1 [12]

  Carmustine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Carmustine increases the expression of SLC10A1 [13]

  Rifampin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Rifampin inhibits the expression of SLC10A1 [10]

  Carbamazepine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Carbamazepine increases the expression of SLC10A1 [14]

  Estradiol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Estradiol inhibits the expression of SLC10A1 [15]

  Lindane

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Lindane inhibits the expression of SLC10A1 [16]

  Tretinoin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tretinoin inhibits the expression of SLC10A1 [17]

  Fenofibrate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Fenofibrate inhibits the expression of SLC10A1 [18]

  Troglitazone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Troglitazone inhibits the expression of SLC10A1 [18]

  Tolvaptan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tolvaptan inhibits the activity of SLC10A1 [19]

  Ethinyl Estradiol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ethinyl Estradiol inhibits the expression of SLC10A1 [20]

  Macitentan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Macitentan inhibits the expression of SLC10A1 [21]

  Acetaminophen

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Acetaminophen inhibits the expression of SLC10A1 [22]

  Valproic Acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Valproic Acid inhibits the expression of SLC10A1 [23]

  Tamoxifen

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tamoxifen increases the expression of SLC10A1 [24]

  Nefazodone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Nefazodone inhibits the expression of SLC10A1 [25]

  Rifampicin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Rifampicin inhibits the activity of SLC10A1 [26]

  Dexamethasone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dexamethasone induces the activity of SLC10A1 [27]

  Ritonavir

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ritonavir inhibits the activity of SLC10A1 [28]

  Adenosine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Adenosine induces the activity of SLC10A1 [29]

  Irbesartan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Irbesartan inhibits the activity of SLC10A1 [30]

Drug in Phase 3 Trial

  Oltipraz

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Oltipraz inhibits the expression of SLC10A1 [10]

  Afimoxifene

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Afimoxifene inhibits the expression of SLC10A1 [24]

  Sulforafan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sulforafan inhibits the expression of SLC10A1 [40]

Drug in Phase 2 Trial

  LUM001

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 LUM001 inhibits the activity of SLC10A1 [43]

Drug in Phase 1 Trial

  Sodium arsenite

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sodium arsenite inhibits the expression of SLC10A1 [37]

  TAK-875

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 TAK-875 inhibits the activity of SLC10A1 [42]

Investigative Drug

  Bromsulphthalein

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Bromsulphthalein inhibits the transportation of Sodium taurocholate by SLC10A1 (IC50 = 7.3 microM) [2]

Affected Drug/Substrate

 Sodium taurocholate Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-NTCP

  Beta-naphthoflavone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Beta-naphthoflavone inhibits the expression of SLC10A1 [32]

  Baohuoside I

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Baohuoside I increases the expression of SLC10A1 [41]

Patented Pharmaceutical Agent

  Ro-41-5253

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ro-41-5253 inhibits the expression of SLC10A1 [17]

Regulation Mechanism

 via the inhibition of Retinoic acid receptor alpha (RARA) Transcription Factor Info

Cell System

 Human hepatocellular carcinoma (HepaRG)

Natural Product

  Cigarette smoke condensate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cigarette smoke condensate inhibits the transportation of Taurocholate by by repressing mRNA expression of SLC10A1 (IC50 = 140 microM) [5]

Affected Drug/Substrate

 Taurocholate Modulation Type Inhibition

Cell System

 Human hepatoma HepaRG cells-NTCP

  Boldine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Boldine induces the activity of SLC10A1 [8]

Cell System

 Model organism in vivo (rat)

  Coal Ash

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Coal Ash inhibits the expression of SLC10A1 [31]

  Particulate Matter

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Particulate Matter inhibits the expression of SLC10A1 [34]

  Heliotrine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Heliotrine inhibits the expression of SLC10A1 [35]

  Tobacco Smoke Pollution

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tobacco Smoke Pollution inhibits the expression of SLC10A1 [5]

  Methyleugenol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Methyleugenol inhibits the expression of SLC10A1 [38]

Dietary Constituent

  Apple juice

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Apple juices inhibits the transportation of Fexofenadine by SLC10A1 [4]

Affected Drug/Substrate

 Fexofenadine Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-NTCP

  DT Modulation 2

 Apple juice inhibits the transportation of Sodium taurocholate by SLC10A1 [4]

Affected Drug/Substrate

 Sodium taurocholate Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-NTCP

Environmental toxicant

  Tetrabromobisphenol A

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tetrabromobisphenol A inhibits the activity of SLC10A1 [36]

  Polychlorinated dibenzodioxin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Polychlorinated dibenzodioxin inhibits the expression of SLC10A1 [5]

Mycotoxins

  Aflatoxin B1

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Aflatoxin B1 inhibits the expression of SLC10A1 [38]

Carcinogen

  Benzo(a)pyrene

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Benzo(a)pyrene inhibits the expression of SLC10A1 [38]

Cyanotoxin

  Cylindrospermopsin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cylindrospermopsin inhibits the expression of SLC10A1 [33]

Pesticide/Insecticide

  Dieldrin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dieldrin inhibits the expression of SLC10A1 [16]

  Endosulfan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Endosulfan inhibits the expression of SLC10A1 [16]

  Heptachlor

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Heptachlor inhibits the expression of SLC10A1 [16]

Health and Environmental Toxicant

  Chlordan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Chlordan inhibits the expression of SLC10A1 [16]

  Perfluorooctane sulfonic acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Perfluorooctane sulfonic acid increases the expression of SLC10A1 [39]
References
1 Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
2 Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity. J Pharmacol Exp Ther. 1999 Dec;291(3):1204-9.
3 Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity. J Pharmacol Exp Ther. 2007 Jun;321(3):1170-8.
4 Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther. 2002 Jan;71(1):11-20.
5 Alteration of human hepatic drug transporter activity and expression by cigarette smoke condensate. Toxicology. 2016 Jul 1;363-364:58-71.
6 Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos. 2005 May;33(5):676-82.
7 Effect of mTOR inhibitors on sodium taurocholate cotransporting polypeptide (NTCP) function in vitro. Front Pharmacol. 2023 Mar 22;14:1147495.
8 Boldine attenuates cholestasis associated with nonalcoholic fatty liver disease in hereditary hypertriglyceridemic rats fed by high-sucrose diet. Physiol Res. 2015;64 Suppl 4:S467-76.
9 Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver. Am J Physiol Gastrointest Liver Physiol. 2005 Nov;289(5):G798-805.; 2005 Nov;289(5):G798-805.
10 Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos. 2006 Oct;34(10):1756-63.
11 Transcriptional profiling in the human prefrontal cortex: evidence for two activational states associated with cocaine abuse. Pharmacogenomics J. 2003;3(1):27-40.
12 The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes. Mol Pharmacol. 2005 Aug;68(2):551-8.
13 Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
14 Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin Pharmacol Ther. 2006 Nov;80(5):440-456.
15 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
16 Regulation of hepatic drug transporter activity and expression by organochlorine pesticides. J Biochem Mol Toxicol. 2014 Mar;28(3):119-28.
17 Dysregulation of retinoic acid receptor diminishes hepatocyte permissiveness to hepatitis B virus infection through modulation of sodium taurocholate cotransporting polypeptide (NTCP) expression. J Biol Chem. 2015 Feb 27;290(9):5673-84.
18 Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
19 Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury?. Toxicol Sci. 2016 Jan;149(1):237-50.
20 UDCA and CDCA alleviate 17alpha-ethinylestradiol-induced cholestasis through PKA-AMPK pathways in rats. Toxicol Appl Pharmacol. 2016 Nov 15;311:12-25.
21 From the Cover: MechanisticInsights in Cytotoxic and Cholestatic Potential of the Endothelial Receptor Antagonists Using HepaRG Cells. Toxicol Sci. 2017 Jun 1;157(2):451-464.
22 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
23 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
24 The formation of estrogen-like tamoxifen metabolites and their influence on enzyme activity and gene expression of ADME genes. Arch Toxicol. 2018 Mar;92(3):1099-1112.
25 Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172.
26 Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2. Hepatology. 2000 Jul;32(1):82-6.
27 Multihormonal regulation of hepatic sinusoidal Ntcp gene expression. Am J Physiol Gastrointest Liver Physiol. 2004 Oct;287(4):G782-94.
28 Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. J Pharmacol Exp Ther. 2006 Sep;318(3):1068-75.
29 Short-term regulation of bile acid uptake by microfilament-dependent translocation of rat ntcp to the plasma membrane. Hepatology. 1999 Jul;30(1):223-9.
30 Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP). Mol Pharm. 2013 Mar 4;10(3):1008-19.
31 Endothelial effects of emission source particles: acute toxic response gene expression profiles. Toxicol In Vitro. 2009 Feb;23(1):67-77.
32 Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 2012 Apr;28(2):69-87.
33 Modulation of chromatin remodelling induced by the freshwater cyanotoxin cylindrospermopsin in human intestinal caco-2 cells. PLoS One. 2014 Jun 12;9(6):e99121.
34 Regulation of human hepatic drug transporter activity and expression by diesel exhaust particle extract. PLoS One. 2015 Mar 24;10(3):e0121232.
35 Disturbance of gene expression in primary human hepatocytes by hepatotoxic pyrrolizidine alkaloids: A whole genome transcriptome analysis. Toxicol In Vitro. 2015 Oct;29(7):1669-82.
36 Inhibition of SLC drug transporter activities by environmental bisphenols. Toxicol In Vitro. 2017 Apr;40:34-44.
37 Cellular and Molecular Effects of Prolonged Low-Level Sodium Arsenite Exposure on Human Hepatic HepaRG Cells. Toxicol Sci. 2018 Apr 1;162(2):676-687.
38 Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297.
39 High-Throughput Transcriptomic Analysis of Human Primary Hepatocyte Spheroids Exposed to Per- and Polyfluoroalkyl Substances as a Platform for Relative Potency Characterization. Toxicol Sci. 2021 May 27;181(2):199-214.
40 Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664.
41 Baohuoside I inhibits FXR signaling pathway to interfere with bile acid homeostasis via targeting ER alpha degradation. Cell Biol Toxicol. 2022 Jul 8.
42 Quantitative Systems Toxicology Analysis of In Vitro Mechanistic Assays Reveals Importance of Bile Acid Accumulation and Mitochondrial Dysfunction in TAK-875-Induced Liver Injury. Toxicol Sci. 2019 Feb 1;167(2):458-467.
43 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.